Lynn Seely Purchases 175,000 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) CEO Lynn Seely purchased 175,000 shares of the business’s stock in a transaction dated Friday, March 14th. The stock was bought at an average cost of $0.61 per share, for a total transaction of $106,750.00. Following the purchase, the chief executive officer now owns 712,500 shares in the company, valued at $434,625. This trade represents a 32.56 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Lyell Immunopharma Trading Down 6.5 %

Shares of Lyell Immunopharma stock opened at $0.48 on Wednesday. The company has a market capitalization of $142.80 million, a PE ratio of -0.61 and a beta of -0.41. Lyell Immunopharma, Inc. has a 12 month low of $0.48 and a 12 month high of $3.15. The stock’s fifty day simple moving average is $0.62 and its 200 day simple moving average is $0.90.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.52). The business had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. Analysts predict that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating and issued a $1.00 price target on shares of Lyell Immunopharma in a research note on Thursday, March 13th.

Institutional Trading of Lyell Immunopharma

Hedge funds have recently added to or reduced their stakes in the business. Decheng Capital LLC bought a new position in Lyell Immunopharma during the 4th quarter worth about $7,622,000. Foresite Capital Management V LLC bought a new position in Lyell Immunopharma during the 4th quarter worth about $5,205,000. venBio Partners LLC bought a new position in Lyell Immunopharma during the 4th quarter worth about $4,545,000. Geode Capital Management LLC increased its holdings in Lyell Immunopharma by 2.9% during the 4th quarter. Geode Capital Management LLC now owns 4,137,264 shares of the company’s stock worth $2,648,000 after purchasing an additional 117,303 shares in the last quarter. Finally, State Street Corp increased its holdings in Lyell Immunopharma by 1.9% during the 3rd quarter. State Street Corp now owns 3,889,553 shares of the company’s stock worth $5,368,000 after purchasing an additional 71,233 shares in the last quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.